Clinical trials: Cisplatin, completed
Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer
BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer
The aim of this study is to investigate the short-term effect and tolerability BP-C1 in patients with metastatic pancreatic cancer who has undergone guideline-recommended chemotherapy.
- Trial name
- NCT03627390
- Testing
- BP-C1, BP-C2
- Where
- Egypt
- Volunteers
- 16 people
- Sponsor
- Meabco A/S
Head and Neck Cancer, Squamous Cell Carcinoma
Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer
The addition of chemotherapy to radiotherapy (chemoradiation) has improved outcomes for patients with locally advanced squamous cell carcinoma of the head and neck but additional improvements to treatment regimens are needed.
- Trial name
- NCT00500760
- Testing
- Cisplatin, Standard Fractionation Radiotherapy, Panitumumab
- Volunteers
- 153 people
- Sponsor
- Amgen
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
This phase II trial studies the side effects of avelumab and how well it works in combination with fluorouracil and mitomycin or cisplatin and radiation therapy in treating participants with muscle-invasive bladder cancer.
- Conditions
- Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8, Stage II Renal Pelvis Cancer AJCC v8, Stage II Ureter Cancer AJCC v8
- Trial name
- NCT03617913
- Testing
- Avelumab, Cisplatin, Fluorouracil
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
This phase II trial investigates whether patients greater than or equal to 65 years of age diagnosed with myeloma or another plasma cell malignancy will have better outcomes with transplant followed by maintenance therapy, as…
- Conditions
- Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease, Primary Systemic Amyloidosis
- Trial name
- NCT01849783
- Testing
- dexamethasone, cisplatin, doxorubicin
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Margarida Magalhaes-Silverman
Liver Cancer
Chemotherapy in Treating Children With Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which chemotherapy regimen is more effective in treating children with liver cancer.
- Trial name
- NCT00003912
- Testing
- carboplatin, cisplatin, doxorubicin hydrochloride
- Where
- Italy
- Volunteers
- 260 people
- Sponsor
- Societe Internationale d'Oncologie Pediatrique
Lung Cancer
Cisplatin, Vinorelbine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as cisplatin and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- SOCCAR (NCT00309972)
- Testing
- Control arm (SEQ):, Experimental arm (CON):
- Where
- United Kingdom
- Volunteers
- 130 people
- Sponsor
- University College, London
HNSCC
Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma
This trial evaluates the addition of pembrolizumab to standard postoperative adjuvant radiochemotherapy in the treatment of patients with locally advanced intermediate and high risk head and neck squamous cell carcinoma (HNSCC).
- Trial name
- NCT03480672
- Testing
- Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA], adjuvant radiochemotherapy
- Where
- 16 sites in Germany
- Volunteers
- 211 people
- Sponsor
- University of Leipzig
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
The purpose of this study is to compare effectiveness of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors…
- Trial name
- NCT04129502
- Testing
- TAK-788, Pemetrexed, Cisplatin
- Where
- 134 sites in United States, Australia and 22 more
- Volunteers
- 354 people
- Sponsor
- Takeda
Head and Neck Cancer
Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer
To evaluate the feasibility and safety of (cohort 1) postoperative standard fractionation radiotherapy plus Iressa and of (cohort 2) hyperfractionated radiotherapy plus cisplatin and Iressa
- Trial name
- IRESSA&H&N (NCT00681967)
- Testing
- Gefitinib
- Where
- 2 sites in Switzerland
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Gastric Cancer
Phase 1/2 Study of S-1 and Cisplatin in Advanced Gastric Cancer
The purpose of the phase 1 portion of the study is to determine the safe dose of S-1 and cisplatin that can be administered in gastric cancer patients.
- Trial name
- NCT00072787
- Testing
- S-1, cisplatin
- Where
- 11 sites in United States
- Volunteers
- 41 people
- Sponsor
- Taiho Oncology, Inc.
Lung Neoplasms
ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.
The purpose of this study is to evaluate the effects (good and bad) of ALIMTA plus Carboplatin or ALIMTA plus Cisplatin on you and your small cell lung cancer.
- Trial name
- NCT00051506
- Testing
- ALIMTA, carboplatin, cisplatin
- Where
- 8 sites in United States
- Sponsor
- Eli Lilly and Company
Transitional Cell Carcinoma
Weekly TP-HDFL in the Treatment of Advanced TCC
The purpose of this study is to evaluate the efficacy of Weekly TP-HDFL in advanced transitional cell carcinoma in terms of response rate and overall survival.
- Trial name
- NCT00154687
- Testing
- Paclitaxel, Cisplatin, 5-Fluorouracil
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Cancer
Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors
JTX-8064-101 is a Phase 1/2, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose (RP2D) of JTX-8064 alone and in combination with a PD-1 inhibitor…
- Trial name
- NCT04669899
- Testing
- JTX-8064, pimivalimab
- Where
- 45 sites in United States
- Volunteers
- 190 people
- Sponsor
- Jounce Therapeutics, Inc.
Lung Cancer
Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as etoposide, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00433498
- Testing
- carboplatin, cisplatin, etoposide phosphate
- Where
- 86 sites in United Kingdom
- Volunteers
- 846 people
- Sponsor
- University College, London
Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma
A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer
The investigators aimed to evaluate the safety of weekly paclitaxel with oncothermia and weekly cisplatin with oncothermia in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal…
- Conditions
- Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- POPOPO (NCT02344095)
- Testing
- weekly paclitaxel, weekly cisplatin, oncothermia
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Seoul National University Hospital
Non-small-cell Lung Cancer, Adenocarcinoma
TS Gene Polymorphism Predicts Effect in Patients With Advanced Lung Cancer
The investigators performed a multicenter, open trial of using TS gene polymorphism to predict advanced lung adenocarcinoma effect to pemetrexed combined with cisplatin regiment as first-line treatment.
- Trial name
- TPEIAL (NCT00940069)
- Testing
- pemetrexed
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hunan Province Tumor Hospital
Lung Cancer
Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy such as irinotecan and cisplatin use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00062322
- Testing
- cisplatin, irinotecan hydrochloride, conventional surgery
- Where
- United States
- Sponsor
- Fox Chase Cancer Center
Cervix Cancer
CAmpto-CISplatine Plus Radiotherapy in Advanced Cervix Cancer : Search of Tolerated Maximum Dose of Campto
Search of maximum tolerated irinotecan dose in association with cisplatin and pelvic radiotherapy in patients with an advanced cervix cancer.
- Trial name
- NCT00251888
- Testing
- campto (irinotecan), cisplatin (cisplatyl)
- Where
- 2 sites in France
- Volunteers
- 15 people
- Sponsor
- ARCAGY/ GINECO GROUP
Advanced Nasopharyngeal Carcinoma
A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma
The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS001sc monotherapy and combination with gemcitabine and cisplatin (GP) in patients with Advanced nasopharyngeal carcinoma.
- Trial name
- NCT05751486
- Testing
- Toripalimab injection(subcutaneous)/JS001sc, Toripalimab /JS001
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00020696
- Testing
- cisplatin, tirapazamine
- Where
- 54 sites in United States, Australia and 2 more
- Sponsor
- Gynecologic Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.